April 4, 2016 Precision medicine brings new hope to those with advanced urothelial cancer Five of six patients with advanced
metastatic urothelial cancer and at least one of two specific genetic abnormalities, responded to treatment with afatinib, which was approved in 2013 by the Food and Drug Administration for patients with lung cancer, researchers report online in the Journal of Clinical Oncology.
The designation is specifically for patients with locally advanced or
metastatic urothelial cancer who have previously been treated with immune checkpoint inhibitors.
Alterations to DDR genes were associated with improved outcomes in patients with
metastatic urothelial carcinoma who were treated with immunotherapy.
The US Food and Drug Administration granted accelerated approval to avelumab (Bavencio) in May 2017, for the treatment of locally advanced or
metastatic urothelial carcinoma patients whose disease progressed on or following platinum - containing chemotherapy.
A Randomized, Double - Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First - line Chemotherapy in Patients with
Metastatic Urothelial Cancer
A Phase III, Multicenter, Randomized, Placebo - Controlled Study of Atezolizumab (ANTI − PD - L1 Antibody) as Monotherapy and in Combination with Platinum - Based Chemotherapy in Patients with Untreated Locally Advanced or
Metastatic Urothelial Carcinoma
Not exact matches
An Open Label, Multicenter, Single Arm Phase II Pilot Study to Evaluate the Efficacy and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK - 228), in Patients with Locally Advanced or
Metastatic Transitional Cell Carcinoma of the
Urothelial Tract whose Tumors Harbor a TSC1 and / or a TSC2 Mutation
• Documented FGF / FGFR alteration and have either 1a) failed at least 1 previous treatment for their
metastatic or surgically unresectable
urothelial carcinoma (ie, chemotherapy, immunotherapy) or 1b) have not received chemotherapy due to poor ECOG status or 2) have insufficient renal function.
Participants have been asked to take part in this research study because they have
metastatic or surgically unresectable
urothelial cancer with FGF / FGFR alterations.
The main purpose of this study is to assess how
metastatic or surgically unresectable
urothelial carcinoma with FGF / FGFR alterations responds to treatment with the study drug, INCB054828.